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Exposure of the general population to a 1:4 lifetime risk of
disabling anxiety has inspired generations of fundamental
and clinical psychopharmacologists, from the era of the
earliest benzodiazepines (BZ) to that of the selective sero-
tonin reuptake inhibitors (SSRIs) and related compounds,
eg, the serotonin and norepinephrine reuptake inhibitors
(SNRIs). This comprehensive practical review summarizes
current therapeutic research across the spectrum of indi-
vidual disorders: generalized anxiety disorder (GAD), panic
disorder (PD) and agoraphobia (social anxiety disorder),
compulsive disorder (OCD), phobic disorder (including
social phobia), and posttraumatic stress disorder (PTSD).
Specific diagnosis is a precondition to successful therapy:
despite substantial overlap, each disorder responds pref-
erentially to specific pharmacotherapy. Comorbidity with
depression is common; hence the success of the SSRIs,
which were originally designed to treat depression.
Assessment (multidomain measures versus individual end
points) remains problematic, as—frequently—do efficacy
and tolerability. The ideal anxiolytic remains the Holy Grail
of worldwide psychopharmacologic research.
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nxiety disorders are the most common and
among the most disabling of mental disorders in adults
and adolescents.
1 Although many are highly circum-
scribed fears of mild-to-moderate severity, it has been
estimated by the Epidemiological Catchment Area
(ECA) study
2 that approximately one quarter of people
will experience severe symptoms,disability,and handicap
as a consequence of anxiety disorders at some time dur-
ing their lifetime.These disorders are associated with sig-
nificant morbidity
3 and increased mortality,probably as
a consequence of increased suicide rates among suffer-
ers.The direct and indirect costs to the health service and
economy are considerable.Although persons who suffer
from anxiety disorders are high consumers of all types of
health services,only a minority receive specific help.
4
The spectrum of anxiety disorders includes generalized
anxiety disorder (GAD),panic disorder (PD) and ago-
raphobia,obsessive-compulsive disorder (OCD),phobic
disorder (including social phobia), and posttraumatic
stress disorder (PTSD).With the discovery of new psy-
chotropic medications,specific diagnosis within this spec-
trum is essential because each of these disorders
responds to specific pharmacotherapy.The approach to
anxiety should also recognize that anxiety and depres-
sion are often comorbid conditions.
Selective serotonin reuptake inhibitors (SSRIs),which
were designed to treat depression,are also effective for
many anxiety disorders.They have revolutionized the
treatment of anxiety,replacing chronic use of benzodi-
azepines (BZs). SSRIs are effective for OCD, PDs,
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phobias, PTSD, and GAD (see Table I). Other anti-
depressants,including tianeptine,have proven effective
in adjustment disorders in which both anxiety and
depression are involved.Doses of SSRIs for anxiety dis-
orders could be higher than those used for depression,
but must be started at lower doses to minimize the short-
term agitation sometimes experienced with these med-
ications.The patient should be counseled that side effects
often diminish with time and also that empirical switch-
ing to another SSRI may be necessary.
Although tricyclic antidepressants (TCAs) have been used
with success in anxiety disorders (Table I),drowsiness,anti-
cholinergic side effects,and toxicity have made these med-
ications less popular.Also,monoamine oxidase inhibitors
(MAOIs) are effective for anxiety,but their dietary restric-
tions and side-effect profile have limited their use.
BZs are the oldest class of medications used to treat
anxiety. Although they have the advantage of rapid
onset of action,they carry the risk of dependence,seda-
tion, and tolerance.Withdrawal syndromes resulting in
rebound anxiety, even reactions as severe as delirium
tremens,are possible.BZs should be avoided in patients
with a past history of substance abuse, personality dis-
order,or dosage escalation.These medications are ideal
for patients who experience infrequent bouts of anxiety
or episodes of anxiety-related insomnia.
Buspirone is a nonbenzodiazepine indicated for GAD.
In head-to-head trials,it works as well as BZs for GAD,
but has a slower onset of action and lacks sedative prop-
erties. It is therefore less useful for the anxious patient
who needs a sedative. It does not impair alertness and
lacks abuse potential.
A number of well-controlled clinical trials support the
empirical evidence of effective pharmacotherapy of anx-
Selected abbreviations and acronyms
BZ benzodiazepine 
GABA γ-aminobutyric acid
GAD generalized anxiety disorder
MAOI monoamine oxidase inhibitors
OCD obsessive-compulsive disorder
PD panic disorder
PTSD posttraumatic stress disorder
RIMA reversible inhibitor of monoamine oxidase A
SNRI serotonin and norepinephrine reuptake inhibitor
SRI serotonin reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressant
Table I. Common medications used in the treatment of anxiety. FDA, Food and Drug Administration; GAD, generalized anxiety disorder; OCD, obses-
sive-compulsive disorder; PD/AG, panic disorder/agoraphobia; PTSD, posttraumatic stress disorder; SAD, social anxiety disorder.
Medication Starting  Therapeutic Common side effects Indications
dose range  (underscore indicates 
(mg) (mg/day) FDA approval)
• Tricyclic antidepressants
Clomipramine 25 25-250 Weight gain, sedation, dry mouth OCD, PD/AG, PTSD, GAD
Imipramine 10-25 150-300 Sedation, dry mouth PD/AG, GAD, PTSD
• Selective serotonin reuptake inhibitors
Citalopram 10 10-60 Nausea, somnolence, dry mouth PD/AG, OCD, PTSD, SAD, GAD
Fluoxetine 5-10 10-80 Nausea, anorexia, insomnia, somnolence OCD, PD/AG, PTSD, SAD, GAD
Fluvoxamine 50 50-300 Nausea, insomnia, somnolence, headache OCD, PD/AG, PTSD, SAD, GAD
Paroxetine 10 10-50 Nausea, somnolence, ejaculation failure OCD, PD/AG, SAD, PTSD, GAD
Sertraline 25 50-200 Nausea, insomnia, ejaculation failure OCD, PD/AG, PTSD, SAD, GAD
• Novel antidepressants
Venlafaxine 37.5 37.5-300 Nausea, dry mouth, insomnia, dizziness GAD, PD/AG
• Other medications
Buspirone 5 (bid) 15-60 Dizziness, nausea GAD
Propranolol 20 20-160 Depression, sedation Performance anxiety
• Benzodiazepines
Alprazolam 0.25 (tid) 0.25-4 Drowsiness, withdrawal GAD, PD/AG, PTSD
Clonazepam 0.25 (bid) 0.25-4 Somnolence, fatigue, depression PD/AG, GAD, PTSD
Lorazepam 0.5 (tid) 1-6 Sedation, dizziness GAD, PD/AG, SADiety disorders. However, the ideal anxiolytic does not
exist,and current research into some new compounds is
very active and promising.Pharmacological treatment evi-
dence for each anxiety disorder will be briefly reviewed.
Generalized anxiety disorder
Benzodiazepines
Several studies have documented that BZs are more
effective than placebo in GAD.
5-9There is also evidence
that BZs may be more effective on specific GAD symp-
toms,particularly the somatic/autonomic symptoms in
contrast to the psychic symptom cluster,which includes
apprehensive worry and irritability.
10 For example,sev-
eral studies have shown that irritability may worsen in
conjunction with high-potency BZs,
11 and that low levels
of depressive symptoms may predict a less favorable
response to BZs.
9 Other data suggest that,although they
respond less well to BZs,psychic symptoms may be more
responsive to other drugs altogether,such as buspirone
or imipramine.
9-10,12 Overall, BZs still remain a widely
used treatment option for GAD,partly no doubt because
of their rapid onset of action, with maximum effect
achieved within 2 weeks,and their generally good toler-
ance
9,13;however,there are few controlled data to support
continued benefits of BZs in the long term in GAD.
Information from some 6 to 8 months’ maintenance ther-
apy trials have found continued efficacy over time,
14-17 but
since GAD is often a long-term and unremitting disor-
der,
18 it needs to be stated that pharmacotherapy,whether
with BZs or other drugs,may need to continue for many
years in a significant number of patients.
Results generally show that approximately 70% of
patients will respond to adequate BZ treatment (up to
40 mg/day of diazepam or equivalent for at least 3-4
weeks), but less than two thirds will achieve remission
of symptoms. In long-term use, tolerance to side effects
does occur, but tolerance to the anxiolytic effect of the
BZs does not appear.
19 With regard to dependence and
withdrawal, compounds with a slower onset of action,
for example,oxazepam,have little reinforcing potential,
while those with a long half-life, for example, diazepam
and chlordiazepoxide, have a lower propensity to pro-
duce withdrawal symptoms, even if stopped abruptly.
Anyway, discontinuation of acute treatment should be
slow because of the potential for rebound anxiety and/or
clinical relapse, and an adequate pretreatment assess-
ment should be an important step to evaluate whether a
subject would be suitable for BZ therapy,including pre-
vious history of withdrawal, liability of abuse, or likeli-
hood of poor compliance. For this reason, and because
of the high prevalence of comorbid depression,attention
has focused also on different medications and antide-
pressants as potential treatment for GAD (Table II).
Azapirones
The first pharmacological treatment for GAD beyond
BZs was the azapirone buspirone, a partial 5-hydroxy-
tryptamine (serotonin, 5-HT)–1A (5-HT1A) agonist,
which decreases the function of postsynaptic 5-HT2
receptors. It has been demonstrated to show efficacy in
GAD
10,20-22 and has been associated with maintenance of
efficacy over a period of several months.
15,16
Buspirone is given in two or three divided doses up to
60 mg/day, and its effect is usually not apparent until 2
to 3 weeks into treatment, in contrast to the almost
immediate effects of BZs.It is not sedating like the BZs;
it is not associated with psychomotor impairment,toler-
ance, dependence, or withdrawal; and it does not inter-
act with alcohol.
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Table II. Generalized anxiety disorder (GAD): therapeutic strategies. BZ, benzodiazepine; SSRI, selective serotonin reuptake inhibitor; TCA, tricylic anti-
depressant.
Predominant clinical features First-line treatment  Partial or no response
• Somatic and autonomically driven symptoms
• History of abuse absent BZ Add or switch to a medication
• Sedation is needed from a different class from the
• Psychic symptoms (apprehensive worry, tension, irritability) starting medication: SSRI or TCA
• Presence of history of abuse Buspirone or buspirone or BZ
• Sedation is not needed or is contraindicated
• Depressive symptoms are intermixed with anxiety SSRI or TCA Add buspirone
• BZs or buspirone are contraindicated or trazodone or BZThe drug works well when there are conspicuous symp-
toms of worry, apprehensive tension, and irritability,
10
and where depressive symptoms are intermixed with
anxiety,
23 while it is less effective than BZs on somatic
and autonomically driven symptoms.
24,25 Patients who
have had previous good responses to BZs do not appear
to respond as well to buspirone,
22 probably due to the
lack of sedative effect and inability to alleviate BZ with-
drawal symptoms, but starting buspirone 2 to 3 weeks
before tapering the BZs has produced better results.
26
Other azapirone drugs have been assessed in GAD,like
gepirone,
27,28 ipsapirone,
29 and more recently flesinoxan
and tandospirone, but with more equivocal results.
Antidepressants
Although antidepressants are now well-established treat-
ments of choice in several anxiety disorders (eg,PD,social
phobia,OCD,and PTSD),their role in the treatment of
GAD remains unclear.Little attention has been given to
the fact that several studies have provided encouraging
support for their efficacy.Perhaps the obscurity of these
findings relates to the general uncertainty about the
nature of GAD,its constantly changing criteria,and the
apparent belief that it is a highly placebo-responsive dis-
order.
30 Early retrospective analyses of subjects with anx-
iety neurosis
21,31 have supported the possible efficacy of tri-
cyclic drugs in GAD-like states.Further controlled trials
by Kahn et al,
32 Hoehn-Saric et al,
12 and Rickels et al
9 have
provided evidence for the benefit of imipramine and tra-
zodone in GAD. Imipramine was more effective than
diazepam on psychic anxiety symptoms,and it would also
be expected to have significant antidepressant effects.Its
reuptake-inhibiting effects on serotonin and norepineph-
rine confer a double advantage relative to some of the
more selective compounds mentioned above.
Trazodone, a serotonin reuptake inhibitor (SRI) and
5-HT2 receptor antagonist, has also been found to be
effective and remains a little-used,but potentially effec-
tive drug for the disorder at doses of up to 400 mg/day,
with doses of 200 to 300 mg/day often being sufficient.
However, due to its side-effect profile, trazodone is
unlikely to be a first choice, but can be a useful backup
drug for more difficult to treat or nonresponsive
patients. Its hypnotic properties are also useful where
insomnia is a major problem.
Nefazodone is a combined SRI,5-HT2 antagonist,and
weak adrenergic antagonist,which may also be benefi-
cial in GAD.Nefazodone enjoys the advantage of greater
patient acceptability and tolerability than trazodone.One
open-label study in GAD has suggested benefit for this
drug,
33 as is also the case for the SSRI paroxetine.
34
The most recent development in the pharmacotherapy
of GAD,largely out of consideration of the results of the
studies with TCAs,has been the controlled comprehen-
sive trials with venlafaxine,a serotonin and norepineph-
rine reuptake inhibitor (SNRI). In five placebo-con-
trolled 8-week trials, venlafaxine has demonstrated
efficacy significantly greater than placebo in the treat-
ment of GAD patients without accompanying depres-
sion. Venlafaxine (75, 150, and 225 mg/day) produced
greater effects than placebo after 1 week of the study,and
these improvements were maintained throughout the
remainder of trials.
35,36These findings were replicated in
a large 6-month trial evaluating long-term treatment of
GAD.Although most of the improvement on venlafax-
ine occurred in the first 4 weeks,subjects continued to
improve over the 6-month period.
37,38 Current trials have
not established an optimal dosage for venlafaxine in the
treatment of GAD, with positive results observed at
dosages as low as 37.5 mg/day. However, data suggest
that 75 to 150 mg/day is probably the most appropriate
dosage range.Mild side effects including nausea,insom-
nia,dry mouth,and dizziness were principally seen at the
initiation of treatment and cleared up over time.
Another double-blind, 8-week study compared ven-
lafaxine (up to 150 mg/day), with buspirone (up to 30
mg/day), and placebo in outpatients with GAD. Both
drugs were superior to placebo,but venlafaxine showed an
earlier effect and advantage over buspirone in secondary
outcome measures, notably the Hamilton Depression
Scale anxiety subscore.
39
The results of these studies indicate that antidepressants
offer promise in GAD, even if they appear to be better
in treating psychic anxiety symptoms, while BZs are
probably superior in treating the somatic symptoms.
40
Other drugs
Several other drugs have been assessed in GAD.The
well-established anxiolytic effects of BZs are modified
by several drawbacks,primarily of physical dependence,
withdrawal symptoms, and sedation.The development
of partial agonists at the γ-aminobutyric acid (GABA)/
BZ receptor complex offers some potential advantages
over the traditional BZs. These BZ-like compounds
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sedation,tolerance,withdrawal,abuse liability,memory
impairment, and ethanol potentiation. These newly
developed compounds are either BZ derivatives or of a
different chemical structure,that is,imidazopyridine and
β-carbolines. The most comprehensively studied has
been the β-carboline abecarnil.In an initial double-blind
trial, Ballenger et al
41 demonstrated clinical efficacy at
doses in the range of 3 to 9 mg/day,without withdrawal
symptoms after short-term treatment.Further placebo-
controlled studies
42,43 have shown modest treatment
effects;however,at higher doses,there is some evidence
of withdrawal symptoms.
Hydroxyzine,an antihistaminergic compound,has been
reported to produce improvement in 60% to 90% of
patients with GAD.
44 It can be very sedating when high
doses are used (50 and 100 mg qid), but a more recent
study
45 showed that it can be effective at low doses (50
mg/day) as well.After 5 weeks of treatment,86% of the
patients improved compared with 47% with placebo,
and the drug was well tolerated.
β-Blockers have been used for the treatment of some
anxiety disorders, but the evidence so far does not sup-
port their use in GAD.
46
Finally, anecdotal experiences report potential value 
of kava and passionflower extract in the treatment of
GAD.
47-49
Panic disorder
Benzodiazepines
Alprazolam, the first licensed BZ for the treatment of
panic,was studied in a large multinational placebo-con-
trolled trial (Cross National Collaborative Panic Study)
conducted in two 8-week phases: during the first it was
compared with placebo, and then it was compared with
both placebo and imipramine. Patients showed signifi-
cant improvements in all major symptom areas, like
number of panic attacks,avoidance behavior,and resid-
ual anxiety between attacks,
50,51 with improvements also
maintained in longer-term studies.
52 Other high-potency
BZs,such as clonazepam
53 and lorazepam,
19 showed sim-
ilar efficacy. BZs are usually well tolerated and they
have a rapid onset of action (1-2 weeks).Potential prob-
lems with long-term use of BZs in PD are tolerance,
dependence,and withdrawal symptoms on discontinua-
tion,but a 2.5-year naturalistic follow-up study found lit-
tle evidence of tolerance to the antipanic effect of alpra-
zolam, and efficacy was maintained without dose
escalation.
54
Although some studies have failed to observe a differ-
ence between alprazolam and imipramine in treatment
of the common comorbid depressive symptoms,
55 several
large meta-analyses have suggested a reduced efficacy
for the BZs compared with TCAs
56 and antidepressants
in general (Table III).
57,58
Antidepressants
Early in the 1960s, investigators documented that
imipramine
59 and the MAOIs, particularly phenelzine,
60
were both effective treatments of PD.
61 Other TCAs also
proved effective, especially clomipramine, and the
improvement was not dependent on the treatment of
concurrent affective symptoms. Following the demon-
stration of efficacy of the non-SSRI clomipramine, a
number of large randomized trials have now demon-
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Table III. Panic disorder (PD): therapeutic strategies. BZ, benzodiazepine; SSRI, selective serotonin reuptake inhibitor; TCA, tricylic antidepressant.
Predominant clinical features First-line treatment  Partial or no response
• Mild symptoms TCA Add a mood stabilizer (valproate, lithium,
• No cardiovascular system pathology or seizure history (clomipramine,  gabapentin) or switch to an SSRI (eventu-
• SSRI intolerability imipramine) ally try venlafaxine or reboxetine)
• Severe symptoms High-potency BZ Add an SSRI, a TCA, or a mood 
• High frequency of attacks (alprazolam, stabilizer (valproate, lithium, gabapentin)
• Invalidating symptoms clonazepam)
• History of abuse absent
• SSRIs are not contraindicated SSRI Add a mood stabilizer (valproate, lithium, 
gabapentin) or switch to a TCA or a dif-
ferent SSRI (eventually try venlafaxine
or reboxetine)strated the efficacy of SSRIs in PD,both in comparison
with placebo and clomipramine.Well-controlled trials
provided evidence
62 that fluvoxamine,paroxetine,citalo-
pram, sertraline, and fluoxetine have similar efficacies,
although comparison trials between different SSRIs are
generally lacking.A recent effect-size analysis of con-
trolled studies of treatment for PD also revealed no sig-
nificant differences between SSRIs and older antide-
pressants in terms of efficacy or tolerability in short-term
trials.
63 As has been observed in all the trials, effective
treatments reduce all the symptoms of PD,the frequency
and severity of panic attacks, agoraphobic avoidance,
anxiety, and comorbid depression.Although there are
different responses of each of these symptoms to these
treatments (eg,agoraphobic avoidance is the most diffi-
cult to treat),successful treatments effectively reduce all
these aspects of the PD syndrome,but appropriate out-
come measures for PD still remain a problem.
64
Reduction of panic-attack frequency has been widely
utilized,but has been unreliable as a single measure,and
most investigators now use multidomain measures.
64
The percentage of patients who become free of panic
attacks is generally 50% to 80% in acute trials lasting 6
to 8 weeks with various medications.
65 In patients who
are treated for longer periods,this percentage most often
rises.It is generally true that the longer PD patients are
treated, the more complete and comprehensive is their
response. In the large Cross-National Collaborative
Panic Study,
66 after 8 to 12 months of treatment, three
fourths of patients were free of panic attacks.In a large
12-month comparison of paroxetine and clomipramine,
the panic-free rates were 85% and 72%,respectively,ris-
ing from about 55% at 3 months.
67
The anxiety that PD patients experience between panic
attacks can be considerable.This anxiety is reduced by
all effective therapies with little difference between
treatments.
56,58 In a similar fashion, most effective treat-
ments decrease the common comorbid depressive symp-
toms, again generally with little difference between
treatments.
65
Agoraphobia is probably the most treatment-resistant
symptom in PD.Although effective pharmacotherapy
does significantly reduce agoraphobia avoidance,in vivo
exposure is often employed to reduce avoidance behav-
iors.There is no standard measure employed in the lit-
erature of improvement in agoraphobic avoidance,mak-
ing comparisons across studies and treatments difficult.
Nonetheless,in a review of 16 studies,
68 remission of ago-
raphobia occurred in ranges varying from 18% to 64%,
and in a 12-month naturalistic study,
69 69% of patients
became free of avoidance.
Improvement in agoraphobic avoidance occurs with all
the effective treatments, probably more or less equally,
although this has not been rigorously studied.The BZs
are as effective as antidepressants in reducing avoidance,
although effects begin earlier with the BZs.
58 Improve-
ment is seen as early as the first or second week with
BZs and as early as the fourth week with the antide-
pressants,
70,71 although improvement in agoraphobia is
often the last portion of the syndrome to respond, and
patients continue to improve for at least 3 to 6 months.
Recent trials suggest that a significant response to anti-
depressants may occur in the first 2 to 4 weeks,which is
earlier than previously thought.
71,72 An important phe-
nomenon in the early stages of treatment (both with
TCAs and SSRIs) could be the paradoxical and tran-
sient increase in anxiety and number of panic attacks,
the so-called “jittering syndrome.”To initiate treatment
at a very low dose, or to cover this first period with a
high-potency BZ, such as clonazepam or alprazolam,
could be useful approaches.
Dietary restrictions and side effects have limited the use
of MAOIs, but the introduction of the reversible
inhibitors of monoamine oxidase A (RIMAs), such as
moclobemide, renewed the interest in this class of
agents.The results,though,so far are conflicting,with an
8-week study showing efficacy for moclobemide in PD,
73
and another one failing to do so.
74
A small case series suggested that venlafaxine may be
effective in the treatment of PD,
75 and mirtazapine pro-
vided good evidence both in an open-label study with a
single-blind placebo run-in period,
76 and in a 8-week
double-blind comparison with fluoxetine.
77 Reboxetine,
a selective norepinephrine reuptake inhibitor was effec-
tive and well tolerated in an 8-week,placebo-controlled,
double-blind trial,
78 with a significant reduction in the
mean number of panic attacks and phobic symptoms at
doses of 6 to 8 mg/day.
Other drugs
Buspirone in PD failed to show any efficacy even at high
doses (60 mg/day).
79 Pagoclone,a cyclopyrrolone that is
believed to act as a partial agonist at the GABAA/BZ
receptor provided some preliminary evidence in a
crossover trial with placebo.
80 β-Blockers provided con-
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but a negative double-blind trial of propranolol with
alprazolam and placebo.
81 Initial evidence suggested that
gabapentin
82 and sodium valproate may be effective in
PD, while carbamazepine is not.
83 Also Ca-channel
blockers have shown mixed results.
84
Social anxiety disorder
Benzodiazepines
There is a limited number of controlled studies testing
BZs in the treatment of social anxiety disorder.
Clonazepam was shown to be effective in one 10-week,
double-blind trial versus placebo, with 78% of patients
responding to an average dosage of 2.4 mg/day.
85 Almost
85% of patients had some response, with 50% having a
marked response and 50% having a moderate one.
There has been only one double-blind study of alprazo-
lam, in which Gelernter et al
86 compared alprazolam
(mean dose 4.2 mg/day) with phenelzine, cognitive
behavioral group therapy, and placebo over a 12-week
period. Only 38% of patients on alprazolam were con-
sidered responders at end point compared with 69% on
phenelzine,24% on cognitive behavioral group therapy,
and 20% on placebo.
Versiani et al
87 conducted a 12-week,double-blind study
to compare bromazepam (mean dose 21 mg/day) to
placebo, with a response rate of 83% of patients on
active drug versus 20% of patients on placebo.
Antidepressants
Only anecdotal evidence supports the efficacy of TCAs
for the treatment of social anxiety disorder,
88 mainly due
to early observations that patients with atypical depres-
sion with marked interpersonal sensitivity and socio-
phobic features show a better response with MAOIs
than TCAs.
89
There were three early controlled trials
86,90,91 in which
phenelzine (up to 90 mg/day) was found to be quite
effective, with 64% of patients obtaining clinically sig-
nificant responses,which increased when treatment was
extended to 4 months.These results were replicated by
Heimberg et al
92 in 1998.
In a comparison between phenelzine and moclobemide,
phenelzine appeared roughly equivalent, but appeared
to work faster.
91 By week 16, 91% of the phenelzine
patients versus 82% of moclobemide patients were
nearly asymptomatic,although moclobemide was better
tolerated. In the Gelernter et al
86 trial, phenelzine was
also better than alprazolam in terms of efficacy.
As mentioned above, RIMAs have also been studied.
Brofaromine (up to 150 mg/day) was promising and
roughly comparable to moclobemide, with response
rates of 80%,
93 78%,
94 and 50%.
95 Moclobemide,after the
promising results of Versiani et al,
91 produced a less
robust result in the large multicenter controlled study
that followed,
96 in which 600 mg/day was superior to
placebo (47% of responders compared with 34% receiv-
ing placebo).Another large multicenter trial,
97 as well a
single study,
98 failed to confirm the efficacy of this drug
in social anxiety.
Certainly the greatest amount of carefully controlled
data are from the recent paroxetine studies.
99-101 In mul-
ticenter, double-blind, placebo-controlled, 12-week tri-
als in severely symptomatic patients with social phobia,
55% of patients had a marked or moderate response at
a mean dosage of 36.6 mg/day. Scores on the Liebowitz
Social Anxiety Scale fell about 40% on paroxetine (30.5
points). Differences were observed in the second week
and throughout the remainder of the trial.These posi-
tive findings were confirmed by Baldwin et al
102 and
Allgulander.
103
Other controlled trials with SSRIs include fluvox-
amine,
88,104 sertraline,
105,106 fluoxetine,
107 venlafaxine,
108 and
nefazodone.
109 In these trials, the clinically significant
response rates of patients were in the 42% to 77%
range.
Finally, open trials of citalopram
110-112 and buproprion
113
have suggested that these drugs may be effective in the
treatment of social anxiety disorder,but controlled stud-
ies are needed to confirm preliminary results.
Other drugs
Buspirone has been shown to be effective as a primary
treatment in two thirds of patients in early trials,
114,115 as
well as an augmenting agent with SSRIs.
116 One con-
trolled trial failed to find significant differences between
buspirone and placebo.
117 Also the β-blocker atenolol,
despite early promise,proved ineffective when tested in
patient populations with generalized symptoms of social
phobia.
90,118 Pindolol was no more effective than placebo
in augmenting the effects of paroxetine treatment for
generalized social phobia.
119
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aging preliminary results in a 14-week, placebo-con-
trolled study.
120 Pregabalin,a follow-up compound of the
GABA agonist gabapentin, is being developed for the
potential treatment of several central nervous system dis-
orders and anxiety,including social anxiety disorder.
121
Posttraumatic stress disorder
Benzodiazepines
PTSD is a complex syndrome occurring after one or more
traumatic events and involves multiple anxiety symptoms,
including flashbacks,emotional numbing,avoidance of
the reminders of the event,and so forth.This disorder was
first recognized after military combat,but is now seen fre-
quently after rape,assault,and accidents.Although there
is no established pharmacotherapy for PTSD,there are
multiple medications that seem to be effective in reduc-
ing these symptoms,particularly flashbacks,phobic avoid-
ance,depression,anxiety,startle reaction,impulsivity,and
hypervigilance (Table IV).BZs seem to be helpful in sup-
pressing hyperarousal symptoms.The first placebo-con-
trolled trial was conducted by Braun et al
122 using alpra-
zolam up to 6 mg/day.Although the core symptoms of the
syndrome (intrusion and avoidant/numbing symptoms)
did not improve significantly compared with placebo,they
reported a positive effect in subjective well-being and a
reduction in anxiety,irritability,and insomnia.Open tri-
als with alprazolam and clonazepam came to similar
results,
123 but withdrawal symptoms were particularly
severe,especially considering the substantial comorbid-
ity of PTSD with alcohol and drug abuse.
O’Brien and Nutt
124 hypothesized that early BZ treat-
ment of trauma survivors may protect toward future
development of PTSD, but the data are still controver-
sial, especially concerning how soon after the event
treatment has to be started to offer this protection.
125
Antidepressants
TCAs have been shown to be helpful in three controlled
trials. Imipramine (up to 300 mg/day) decreased intru-
sive thoughts,nightmares,and flashbacks with no effect
on numbing or avoidance in an 8-week study.
126,127
Amitriptyline (up to 300 mg/day) has also been shown
to reduce avoidance and anxiety in an 8-week trial, but
it had no effect in the re-experiencing of intrusive
thoughts and images.
128 Desipramine failed to show any
advantage over placebo in a 4-week study,
129 but at rela-
tively low doses compared with the two previous trials.
Moreover, as highlighted by Friedman,
123 TCAs have
been tested mainly on samples of veterans with severe
chronic PTSD, while SSRIs and MAOIs have been
tested in nonveteran samples.An important finding aris-
ing from these studies is the lack of placebo response in
PTSD compared with other anxiety disorders.
MAOIs have also been shown to be effective
(phenelzine up to 75 mg/day) in reducing intrusive
thoughts and flashbacks after 8 weeks of treatment,
126
but other trials have failed to observe positive effects.
130
MAOIs appear to produce moderate to good clinical
improvement,primarily affecting PTSD intrusive recol-
lections,flashbacks,and nightmares,while hyperarousal,
numbing,and avoidance behavior are scarcely affected.
In addition,the usual dietary and medication restrictions
of the MAOIs are more problematic in this patient
group, given the high incidence of substance abuse.
123
Early trials with combat veterans suggest that the
reversible MAOI moclobemide is promising.
131
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Table IV. Posttraumatic stress disorder (PTSD): therapeutic strategies. SSRI, selective serotonin reuptake inhibitor; TCA, tricylic antidepressant.
Predominant clinical features First-line treatment  Partial or no response
• Intusive thoughts and flashbacks,  SSRI (fluoxetine, paroxetine, sertraline) 
hyperarousal, impulsivity or mood stabilizer (carbamazepine, 
lithium, valproate)
• Anxiety without severe depression,  Alprazolam, clonazepam, or buspirone
irritability, insomnia
• Depressive symptoms SSRI (fluoxetine, paroxetine, sertraline),
or TCA (imipramine, amitriptyline),
or phenelzine
• Psychotic symptoms, aggressivity,  Olanzapine
or agitation
SSRI and/or mood stabilizer
(also topiramate and gabapentin)
combination
Add nefazodone or trazodone
for concurrent sleep disordersSSRIs have been observed to be helpful in open stud-
ies,especially with fluoxetine up to 80 mg/day.
132,133This
has been confirmed in a placebo-controlled trial of
veteran and civilian trauma victims.
134 Approximately
two thirds of patients experienced decreases in the
core symptoms of PTSD including hyperarousal,
numbing, avoidance, and intrusive images. Penava et
al
135 conducted an effect-size analysis of controlled
studies where fluoxetine showed the biggest effect
compared with the other antidepressant and BZs stud-
ied so far.
Sertraline has also been reported effective
136 in long-
term treatment
137,138 and paroxetine (20-40 mg/day) was
superior than placebo in two recent 12-week, double-
blind studies.
139,140
Nefazodone (350-450 mg/day) has been shown to sig-
nificantly improve most symptoms, including intrusive
thoughts,avoidant behaviors,emotional numbing,night-
mares,sleep,depression,and anger,
141,142 and there is only
anecdotal evidence for improvement with trazodone.
123
Other drugs
The anticonvulsant carbamazepine has been shown to
decrease flashbacks, hyperarousal, and impulsivity.
143,144
Lithium and valproic acid may be helpful as well,
145-147
particularly in patients with poor impulse control.
148
Open-label topiramate
149 and gabapentin
150 appeared
effective as add-on therapy for chronic PTSD.
Buspirone (15-35 mg/day) was reported to be effective
in reducing anxiety,insomnia,flashbacks,and depressed
mood in three PTSD war veterans after 2 weeks of treat-
ment.
151
Some case reports with atypical neuroleptics and an
open-label study with olanzapine have been positive for
the treatment of the core symptoms and the psychotic
symptoms that PTSD patients may exhibit.
123,152
Open-label propranolol (120-160 mg/day) improved
hyperarousal,sleep,nightmares,explosiveness,and psy-
chosocial functioning in 11 out of 12 Vietnam veterans,
153
and acute, posttrauma propranolol may have a preven-
tive effect on subsequent PTSD.
154
The α1-adrenergic antagonist prazosin
155 and α2-adren-
ergic agonists clonidine and guanfacine also provided
some preliminary promising results.
123,153
Obsessive-compulsive disorder
Benzodiazepines
BZs are not a first-choice treatment for OCD (Table V),
and few data exist to date. Clonazepam, a BZ that also
affects serotonergic transmission, was compared with
clomipramine and clonidine in a crossover,double-blind
study with each treatment lasting for 6 weeks.
156The first
two drugs were equally effective, while clonidine was
largely ineffective. Clonazepam provided an early
improvement (2-3 weeks),unrelated to changes in anx-
iety,and there was a significant cross-response between
clomipramine and clonazepam,with patients who failed
on clomipramine showing a clinically significant
response to clonazepam.
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Table V. Obsessive-compulsive disorder (OCD): therapeutic strategies. BZ, benzodiazepine; MAOI, monoamine oxidase inhibitor; SNRI, serotonin and
norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricylic antidepressant.
Predominant clinical features First-line treatment  Partial or no response
• Depressive symptoms, recurrent  Add mood stabilizer (lithium, gabapentin)
course with bipolar
spectrum comorbidity
• Highly anxious obsessional subjects  Add BZ (clonazepam)
• Prevalent symmetry and atypical Add MAOI or SNRI and eventually neuroleptic
obsession or high level of
anxiety to treatment
• Severe hoarding symptoms  Add different typical/atypical neuroleptic
(pimozide, haloperidol, risperidone, olanzapine)
• Tics, psychotic symptoms Add different typical/atypical neuroleptic
(pimozide, haloperidol, risperidone, olanzapine)
SSRI
Eventually switch to a 
different SSRI or SRI
(clomipramine or intra-
venous clomipramine)
(Potentiation with 
buspirone, clonazepam,
tryptophan, pindolol)Antidepressants
Pharmacological investigations have demonstrated that
OCD responds selectively to drugs that act as potent
inhibitors of the synaptic reuptake of serotonin.The first
medication demonstrated to be effective in OCD was
clomipramine (150-250 mg/day) with 40% of patients
(versus 4% for placebo) having a clinically significant
decrease in symptoms independently of its antidepres-
sant effect.
157-159 Subsequently,all of the SSRIs have been
shown to be effective, including fluvoxamine (100-300
mg/day), fluoxetine (20-80 mg/day), paroxetine (40-60
mg/day),sertraline (50-200 mg/day),and citalopram (20-
60 mg/day).
159 Most recent controlled trials find that
about 50% of patients experience a 25% to 35% drop in
scale scores of OCD,primarily utilizing the Yale-Brown
Obsessive Compulsive Scale (Y-BOCS).This magnitude
of change typically results in significant improvement in
function;however,interfering symptoms usually persist.
Relative efficacy between the SRIs has been difficult to
determine.Two meta-analysis suggested greater efficacy
for chlorimipramine
160,161;however,these trials were per-
formed over a 7- to 10-year time period, during which
placebo rates rose significantly, making any conclusion
suspect. In fact, in several head-to-head trials, clomi-
pramine was found to have equal efficacy to fluoxe-
tine,
162 paroxetine,
163 and sertraline,
164 with SSRIs being
better tolerated than clomipramine. A more recent
meta-analysis generally failed to find any significant dif-
ference between the SRIs, although it again suggested
some advantage for clomipramine.However,this meta-
analysis involved many of the trials mentioned above
and has the same problem in interpretation.
165There was
no observed difference in a trial comparing fluvoxam-
ine,paroxetine,and citalopram.
166
Due to their similar effects, it is difficult to choose
between SSRIs, and the selection of a drug largely
depends upon personal preference,even if the possibil-
ity of a drug interaction or the various pharmacokinetic
profiles could influence the choice. Dosages of these
medications have often been described as being signifi-
cantly higher than antidepressant dosages (eg, 60-80
mg/day fluoxetine); however, in large carefully con-
trolled trials,there has been no observed significant dif-
ference between response to higher and lower dosages
for the SSRIs (eg, 50 and 200 mg/day sertraline).
167 This
clinical impression may well relate to the slow onset of
effectiveness with many patients taking 10 to 12 weeks
to improve (longer than 4-8 weeks for depression),dur-
ing which physicians continue to raise the patients’ doses,
mistakenly thinking it was the increased dose,not time,
that was responsible for improvement.For this reason,it
is helpful to warn patients about this from the outset,and
slowly titrate doses upwards to avoid side effects.
Many patients will not respond or will partially respond
to the first SSRI,but will respond to another antiobses-
sional agent.Therefore, sequential trials are frequently
required, which easily can take up to a year to accom-
plish.
Limited available evidence suggests that when effective
pharmacotherapy is discontinued, most patients (90%)
do relapse.
168 Therefore, current practice is to continue
effective pharmacotherapy for at least 1 to 2 years or
indefinitely.In a large extension study by Greist et al,
167
118 patients who had responded to 12 weeks’ treatment
with either sertraline or placebo continued their treat-
ment,in a double-blind way,for 40 weeks.Therapy gains
with sertraline were maintained with continued med-
ication as long as they remained on active medication,
without tolerance developing.The 59 patients who com-
pleted this study were followed up for a second year on
open-label sertraline,whereupon they showed additional
clinical improvements.
169 Another trial with paroxetine
demonstrated continued efficacy for 12 months in the
majority of patients.
170
The effectiveness of potent SRIs is now well established
in the treatment of OCD, but despite these advances,
nearly 40% to 60% of patients experience minimal to no
improvement in symptoms with these treatments.
Furthermore, in patients who do respond to SRIs, the
degree of improvement is often incomplete, with few
patients experiencing full symptom remission.
171 For
these reasons,attempts to augment or improve the aver-
age response with pharmacological strategies targeting
serotonergic or other neurotransmitter systems are rou-
tine.There is no agent that is routinely effective as an
augmenting agent, although there is some support for
clonazepam, clonidine, trazodone, nefazodone, trypto-
phan, and pindolol.
172 There is clear evidence of benefit
for traditional neuroleptics
173 and more recently the
atypical neuroleptics (eg, risperidone, olanzapine, and
quetiapine), principally in the patients with OCD who
have comorbid tic disorders.
174-177
Intravenous clomipramine has also been shown to be
more effective than oral administration.
178,179
Two controlled studies were performed to test the
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180
found phenelzine (up to 75 mg/day) and clomipramine
(up to 225 mg/day) both effective with no significant dif-
ference between the two drugs,while another one com-
paring phenelzine (60 mg/day) with fluoxetine (80
mg/day) and placebo found that phenelzine was no bet-
ter than placebo.
181
Other drugs
Buspirone produced an effect similar to clomipramine
in a small double-blind study with 18 patients,
182 but the
results from controlled trials of buspirone augmentation
to SRIs were less encouraging.
183,184
Inositol (18 mg/day) was superior to placebo and well
tolerated in a short-term, double-blind, controlled trial
with crossover design performed in OCD.
185
Lithium has been suggested to further reduce obsessive-
compulsive symptoms when added to therapy with anti-
depressants,
186-188 although controlled studies have not
substantiated these observations,
189 and gabapentin was
reported to further reduce OC symptoms when added
in an open-label manner to ongoing fluoxetine (30-100
mg/day) treatment in five OCD patients.
190 ❏
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Psicofarmacología de los trastornos de
ansiedad
La población general se expone a un riesgo de vida
de 1:4 para la ansiedad incapacitante, lo que ha ins-
pirado a generaciones de psicofarmacólogos básicos
y clínicos, desde la época de las primeras benzodia-
zepinas (BZ) hasta la de los inhibidores selectivos de
la recaptación de serotonina (ISRS) y compuestos rela-
cionados, por ejemplo, los inhibidores de la recapta-
ción de serotonina y de noradrenalina (IRSN). Este
extenso y práctico artículo de revisión resume la
investigación terapéutica actual a través del espectro
de los trastornos individuales: trastorno de ansiedad
generalizada (TAG), trastorno de pánico (TP) y ago-
rafobia (trastorno de ansiedad social), trastorno com-
pulsivo (TOC), trastorno fóbico (incluyendo la fobia
social) y el trastorno por estrés postraumático (TEPT).
El diagnóstico específico es una condición previa para
una terapia exitosa: a pesar de una considerable
sobreposición, cada trastorno responde de preferen-
cia a una terapia farmacológica específica. La comor-
bilidad con la depresión es frecuente; de ahí el éxito
de los ISRS, los cuales fueron originalmente diseña-
dos para tratar la depresión. La evaluación sigue
siendo un problema (mediciones multivariadas ver-
sus puntuación final individual), al igual que – con
frecuencia – evaluar la eficacia y la tolerancia. El
ansiolítico ideal sigue siendo el “Santo Grial” de la
investigación psicofarmacológica mundial.
Psychopharmacologie des troubles anxieux
Dans la population générale, l’exposition au risque
d’anxiété invalidante est de 1/4 au cours de la vie;
ceci a inspiré des générations de psychopharmaco-
logues fondamentalistes et cliniques, de l’ère des
premières benzodiazépines (BZ) à celle des inhibi-
teurs sélectifs de la recapture de la sérotonine
(ISRS) et autres composés apparentés, par ex. la
sérotonine et les inhibiteurs de la recapture de la
noradrénaline (IRN). La présente analyse pratique
résume de façon exhaustive la recherche théra-
peutique actuelle à travers un éventail de troubles
tels que : anxiété généralisée (TAG), trouble
panique (TP) et agoraphobie (trouble anxieux
social), trouble compulsif  (TOC), névrose phobique
(y compris la phobie sociale), et névrose de stress
posttraumatique (TSPT). Un diagnostic spécifique
est le prérequis d’un traitement efficace : en dépit
des intrications importantes, chaque trouble
répond de façon préférentielle à une pharmaco-
thérapie spécifique. La comorbidité avec la dépres-
sion est fréquente ; d’où le succès des ISRS, qui
étaient au départ conçus pour le traitement de la
dépression. L’évaluation (mesures dans plusieurs
domaines versus critères individuels) reste problé-
matique, comme le sont - souvent - l’efficacité et la
tolérance. L’anxiolytique idéal demeure la quête du
Graal de la recherche psychopharmacologique
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